MedTrace Logo

Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation

NCT04338958 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 193

Last updated 2021-08-13

No results posted yet for this study

Summary

RuxCoFlam is a single arm, non-randomized open phase II trial for front line treatment of Covid-19 patients with defined hyperinflammation.

Conditions

Interventions

DRUG

Ruxolitinib

2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment

Sponsors & Collaborators

  • University of Jena

    lead OTHER

Principal Investigators

  • Andreas Hochhaus, Prof. Dr. · University Hospital Jena

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-22
Primary Completion
2021-07-15
Completion
2021-07-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04338958 on ClinicalTrials.gov